171 related articles for article (PubMed ID: 20959843)
1. The role of clinical pharmacology in supporting the emergency use authorization of an unapproved anti-influenza drug, peramivir.
Arya V; Carter WW; Robertson SM
Clin Pharmacol Ther; 2010 Nov; 88(5):587-9. PubMed ID: 20959843
[TBL] [Abstract][Full Text] [Related]
2. The emergency use authorization of peramivir IV: a view from the manufacturer.
Hollister AS; Sheridan WP
Clin Pharmacol Ther; 2011 Feb; 89(2):172-4. PubMed ID: 21252934
[TBL] [Abstract][Full Text] [Related]
3. Emergency use authorization for intravenous peramivir: evaluation of safety in the treatment of hospitalized patients infected with 2009 H1N1 influenza A virus.
Sorbello A; Jones SC; Carter W; Struble K; Boucher R; Truffa M; Birnkrant D; Gada N; Camilli S; Chan I; Dallas S; Scales T; Kosko R; Thompson E; Goodman J; Francis H; Dal Pan G
Clin Infect Dis; 2012 Jul; 55(1):1-7. PubMed ID: 22491501
[TBL] [Abstract][Full Text] [Related]
4. Peramivir: an intravenous neuraminidase inhibitor for the treatment of 2009 H1N1 influenza.
Mancuso CE; Gabay MP; Steinke LM; Vanosdol SJ
Ann Pharmacother; 2010; 44(7-8):1240-9. PubMed ID: 20516360
[TBL] [Abstract][Full Text] [Related]
5. The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza.
Birnkrant D; Cox E
N Engl J Med; 2009 Dec; 361(23):2204-7. PubMed ID: 19884645
[No Abstract] [Full Text] [Related]
6. Peramivir use for treatment of hospitalized patients with influenza A(H1N1)pdm09 under emergency use authorization, October 2009-June 2010.
Yu Y; Garg S; Yu PA; Kim HJ; Patel A; Merlin T; Redd S; Uyeki TM
Clin Infect Dis; 2012 Jul; 55(1):8-15. PubMed ID: 22491506
[TBL] [Abstract][Full Text] [Related]
7. Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir. II: a pediatric drug use investigation.
Komeda T; Ishii S; Itoh Y; Ariyasu Y; Sanekata M; Yoshikawa T; Shimada J
J Infect Chemother; 2015 Mar; 21(3):194-201. PubMed ID: 25523716
[TBL] [Abstract][Full Text] [Related]
8. Peramivir for the treatment of influenza.
Shetty AK; Peek LA
Expert Rev Anti Infect Ther; 2012 Feb; 10(2):123-43. PubMed ID: 22339187
[TBL] [Abstract][Full Text] [Related]
9. Peramivir and its use in H1N1 influenza.
Castillo R; Holland LE; Boltz DA
Drugs Today (Barc); 2010 Jun; 46(6):399-408. PubMed ID: 20571608
[TBL] [Abstract][Full Text] [Related]
10. Intravenous peramivir for treatment of influenza in hospitalized patients.
Ison MG; Fraiz J; Heller B; Jauregui L; Mills G; O'Riordan W; O'Neil B; Playford EG; Rolf JD; Sada-Diaz E; Elder J; Collis P; Hernandez JE; Sheridan WP
Antivir Ther; 2014; 19(4):349-61. PubMed ID: 23985625
[TBL] [Abstract][Full Text] [Related]
11. Response to several recent publications related to safety and efficacy of peramivir from the emergency use authorization experience.
Ison MG; Hollister AS; Sheridan WP
Clin Infect Dis; 2013 Jan; 56(1):164. PubMed ID: 22972863
[No Abstract] [Full Text] [Related]
12. [Emergency admission of peramivir in the U.S.A].
Bennack E; Holzgrabe U
Pharm Unserer Zeit; 2010; 39(1):9-10. PubMed ID: 20033965
[No Abstract] [Full Text] [Related]
13. Peramivir clearance in continuous renal replacement therapy.
Thomas B; Hollister AS; Muczynski KA
Hemodial Int; 2010 Jul; 14(3):339-40. PubMed ID: 20491974
[No Abstract] [Full Text] [Related]
14. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States.
Hernandez JE; Adiga R; Armstrong R; Bazan J; Bonilla H; Bradley J; Dretler R; Ison MG; Mangino JE; Maroushek S; Shetty AK; Wald A; Ziebold C; Elder J; Hollister AS; Sheridan W;
Clin Infect Dis; 2011 Mar; 52(6):695-706. PubMed ID: 21367722
[TBL] [Abstract][Full Text] [Related]
15. Peramivir: another tool for influenza treatment?
Jain S; Fry AM
Clin Infect Dis; 2011 Mar; 52(6):707-9. PubMed ID: 21367723
[No Abstract] [Full Text] [Related]
16. Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection.
Sugaya N; Kohno S; Ishibashi T; Wajima T; Takahashi T
Antimicrob Agents Chemother; 2012 Jan; 56(1):369-77. PubMed ID: 22024821
[TBL] [Abstract][Full Text] [Related]
17. Emergency-use authorization of peramivir.
Gonzalez R; Massoomi F; Neff W
Am J Health Syst Pharm; 2009 Dec; 66(24):2162-3. PubMed ID: 19966083
[No Abstract] [Full Text] [Related]
18. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment.
Barroso L; Treanor J; Gubareva L; Hayden FG
Antivir Ther; 2005; 10(8):901-10. PubMed ID: 16430195
[TBL] [Abstract][Full Text] [Related]
19. Emergency authorization of medical products: regulatory challenges from the 2009 H1N1 influenza pandemic in Japan.
Urushihara H; Matsui S; Kawakami K
Biosecur Bioterror; 2012 Dec; 10(4):372-82. PubMed ID: 23210832
[TBL] [Abstract][Full Text] [Related]
20. Post-marketing safety evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir: A drug-use investigation in patients with high risk factors.
Komeda T; Ishii S; Itoh Y; Sanekata M; Yoshikawa T; Shimada J
J Infect Chemother; 2016 Oct; 22(10):677-84. PubMed ID: 27497712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
